- Home
- PHAT vs NAGE Comparison
PHAT vs NAGE Comparison
Compare PHAT & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NAGE
- Stock Information
- Founded
- PHAT 2018
- NAGE 1999
- Country
- PHAT United States
- NAGE United States
- Employees
- PHAT N/A
- NAGE N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- PHAT Health Care
- NAGE Health Care
- Exchange
- PHAT Nasdaq
- NAGE Nasdaq
- Market Cap
- PHAT 727.5M
- NAGE 861.0M
- IPO Year
- PHAT 2019
- NAGE N/A
- Fundamental
- Price
- PHAT $9.45
- NAGE $11.41
- Analyst Decision
- PHAT Strong Buy
- NAGE Strong Buy
- Analyst Count
- PHAT 5
- NAGE 3
- Target Price
- PHAT $16.40
- NAGE $16.67
- AVG Volume (30 Days)
- PHAT 1.7M
- NAGE 1.1M
- Earning Date
- PHAT 08-07-2025
- NAGE 08-06-2025
- Dividend Yield
- PHAT N/A
- NAGE N/A
- EPS Growth
- PHAT N/A
- NAGE N/A
- EPS
- PHAT N/A
- NAGE 0.18
- Revenue
- PHAT $81,859,000.00
- NAGE $107,925,000.00
- Revenue This Year
- PHAT $195.03
- NAGE $26.44
- Revenue Next Year
- PHAT $106.77
- NAGE $20.06
- P/E Ratio
- PHAT N/A
- NAGE $63.14
- Revenue Growth
- PHAT 3055.70
- NAGE 29.77
- 52 Week Low
- PHAT $2.21
- NAGE $2.52
- 52 Week High
- PHAT $19.71
- NAGE $14.69
- Technical
- Relative Strength Index (RSI)
- PHAT 60.80
- NAGE N/A
- Support Level
- PHAT $8.19
- NAGE N/A
- Resistance Level
- PHAT $9.76
- NAGE N/A
- Average True Range (ATR)
- PHAT 0.66
- NAGE 0.00
- MACD
- PHAT -0.21
- NAGE 0.00
- Stochastic Oscillator
- PHAT 54.58
- NAGE 0.00
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.